Q-omics provides the consensus-scored MIR6722 profile across patient tissues and cancer cell-line models. MIR6722 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MIR6722 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR6722 RNA expression shows 5,729 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, BRCA, and STAD as cancer lineages where MIR6722 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6722 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6722 survival associations across molecular data types. MIR6722 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6722 RNA expression–survival associations across cancer types. High MIR6722 expression shows unfavorable associations in LUSC, LUAD, ACC, SKCM and COAD, but favorable associations in ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for MIR6722 RNA expression.
This table summarizes MIR6722 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6722. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6722 shows lower tumor expression in BRCA, LUAD and KICH and higher tumor expression in THCA. The BRCA box plot shows higher MIR6722 RNA expression in normal versus tumor tissue (log2 FC = −0.239, t-test p < 0.001).
This table shows molecular features associated with MIR6722 in patient tissues and cancer cell lines. In patient samples, MIR6722 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
